Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery
NCT02189889 · University of Texas Southwestern Medical Center · PHASE1/PHASE2 · terminated · last registry update 2020-10-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Initial patients were seen at St Paul Hospital. Enrollment changes occurred with the move to Clements Hospital. We were unable to identify an infusion room at CUH despite an exhaustive search for alternatives and forced to terminate early.” | – | Registry record, University of Texas Southwestern Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EPOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-10-20Results posted on the registry: GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT03029208)
- 2021-10-15Phase 3 first posted: University Hospital, Angers, Erythropoietin + Placebo (NCT05080049)
- 2021-10-01Results posted on the registry: Kyntra Bio, Roxadustat + Epoetin Alfa (NCT02052310)
- 2021-10-01Results posted on the registry: Kyntra Bio, Roxadustat + Oral Iron (NCT01414075)
- 2021-10-01Results posted on the registry: Kyntra Bio, Roxadustat (NCT01630889)
- 2021-09-29Also stopped (withdrawn): Seoul National University Hospital, Erythropoietin (NCT03004209)
- 2021-08-06Also stopped (withdrawn): University of Louisville, Procrit + Placebo (NCT00624312)
- 2021-07-21Results posted on the registry: GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT03446612)
- 2021-07-13Also stopped (terminated): Shire, Dynepo (NCT00514813)
- 2021-07-12Results posted on the registry: GlaxoSmithKline, Daprodustat tablets + Matching placebo tablets (NCT03400033)
- 2021-07-08Results posted on the registry: National Cancer Institute (NCI), Epoetin Alfa + Lenalidomide (NCT00843882)
- 2021-06-24Also stopped (terminated): Sanofi, Oral Iron + sodium ferric gluconate (NCT00223938)
- 2021-06-18Also stopped (terminated): Unity Health Toronto, Iron sucrose + Epoetin Alfa (NCT03528564)
- 2021-06-14Also stopped (terminated): Shire, Dynepo (Epoetin delta) + Dynepo (NCT00450333)
- 2021-06-03Results posted on the registry: GlaxoSmithKline, Daprodustat + Epoetin alfa (NCT03029247)
- 2021-06-02Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, recombinant human erythropoietin (NCT04910594)
- 2021-04-12Results posted on the registry: Tanabe Pharma Corporation, MT-6548 + Darbepoetin alfa (NCT03329196)
- 2021-04-12Results posted on the registry: Tanabe Pharma Corporation, MT-6548 + Darbepoetin alfa (NCT03439137)
- 2021-03-29Results posted on the registry: Astellas Pharma Europe B.V., Roxadustat + Darbepoetin alfa (NCT02021318)
- 2021-03-09Results posted on the registry: Imperial College Healthcare NHS Trust, Iron sucrose + Erythopoietin stimulating agent (NCT02707757)
- 2021-02-21Results posted on the registry: Akebia Therapeutics, vadadustat + epoetin alfa (NCT03140722)
- 2021-02-21Also stopped (terminated): Akebia Therapeutics, vadadustat + epoetin alfa (NCT03140722)
- 2021-01-13Phase 3 first posted: Akebia Therapeutics, Vadadustat + Mircera® (NCT04707768)
- 2020-11-12Results posted on the registry: Memorial Sloan Kettering Cancer Center, darbepoetin alfa + filgrastim (NCT00058422)
- 2020-10-22Also stopped (terminated): Shenyang Sunshine Pharmaceutical Co., LTD., EPIAO® + EPREX® (NCT02522975)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision